JP7561348B2 - 間葉系幹細胞の増殖促進または減少抑制のための組成物 - Google Patents

間葉系幹細胞の増殖促進または減少抑制のための組成物 Download PDF

Info

Publication number
JP7561348B2
JP7561348B2 JP2021535424A JP2021535424A JP7561348B2 JP 7561348 B2 JP7561348 B2 JP 7561348B2 JP 2021535424 A JP2021535424 A JP 2021535424A JP 2021535424 A JP2021535424 A JP 2021535424A JP 7561348 B2 JP7561348 B2 JP 7561348B2
Authority
JP
Japan
Prior art keywords
serpin
dss
mesenchymal stem
cells
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021535424A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021020509A1 (https=
JPWO2021020509A5 (https=
Inventor
克人 玉井
敬史 新保
尊彦 山崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
StemRIM Inc
University of Osaka NUC
Original Assignee
Osaka University NUC
StemRIM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, StemRIM Inc filed Critical Osaka University NUC
Publication of JPWO2021020509A1 publication Critical patent/JPWO2021020509A1/ja
Publication of JPWO2021020509A5 publication Critical patent/JPWO2021020509A5/ja
Application granted granted Critical
Publication of JP7561348B2 publication Critical patent/JP7561348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021535424A 2019-07-31 2020-07-30 間葉系幹細胞の増殖促進または減少抑制のための組成物 Active JP7561348B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019141325 2019-07-31
JP2019141325 2019-07-31
JP2020058544 2020-03-27
JP2020058544 2020-03-27
PCT/JP2020/029229 WO2021020509A1 (ja) 2019-07-31 2020-07-30 間葉系幹細胞の増殖促進または減少抑制のための組成物

Publications (3)

Publication Number Publication Date
JPWO2021020509A1 JPWO2021020509A1 (https=) 2021-02-04
JPWO2021020509A5 JPWO2021020509A5 (https=) 2023-08-07
JP7561348B2 true JP7561348B2 (ja) 2024-10-04

Family

ID=74230673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535424A Active JP7561348B2 (ja) 2019-07-31 2020-07-30 間葉系幹細胞の増殖促進または減少抑制のための組成物

Country Status (3)

Country Link
US (1) US20220265787A1 (https=)
JP (1) JP7561348B2 (https=)
WO (1) WO2021020509A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3556378B1 (en) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053892A1 (en) 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceutical for promoting functional regeneration of damaged tissue
WO2009133939A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
JP2018502579A (ja) 2015-01-08 2018-02-01 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008242A (en) * 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US5674708A (en) * 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053892A1 (en) 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceutical for promoting functional regeneration of damaged tissue
WO2009133939A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
JP2018502579A (ja) 2015-01-08 2018-02-01 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
織間一郎，炎症性腸疾患における好中球エラスターゼの測定およびその意義，杏林医学会雑誌，1994年，Vol.25, No.4, pp.537-544

Also Published As

Publication number Publication date
JPWO2021020509A1 (https=) 2021-02-04
US20220265787A1 (en) 2022-08-25
WO2021020509A1 (ja) 2021-02-04

Similar Documents

Publication Publication Date Title
JP5814549B2 (ja) 損傷組織の機能的再生促進医薬
JP6199936B2 (ja) 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
CN113194978B (zh) 具有间充质干细胞的动员活性的肽
EP4291239A2 (en) Compounds, compositions and methods for treating age-related diseases and conditions
US20240368235A1 (en) Disease Treatment Drug Based on Mesenchymal-Stem-Cell Mobilization
JP7561348B2 (ja) 間葉系幹細胞の増殖促進または減少抑制のための組成物
JP7672636B2 (ja) 間葉系幹細胞の動員活性を有するペプチド
JP6577261B2 (ja) 脊柱靱帯骨化症モデル非ヒト動物、糖尿病モデル非ヒト動物、脊柱靱帯骨化症モデル細胞、糖尿病モデル細胞、スクリーニング方法、脊柱靱帯骨化症病変細胞の検出方法、脊柱靱帯骨化症診断用キット、及び脊柱靱帯骨化症治療剤
CN116492463A (zh) Cd155分子在肝纤维化领域中的应用
JP7016125B2 (ja) 脳梗塞の治療薬
JP5187875B2 (ja) 心肥大ならびに拡張型心筋症非ヒトモデル動物
HK1156211A (en) Pharmaceutical agent for promoting the functional regeneration of damaged tissue

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240911

R150 Certificate of patent or registration of utility model

Ref document number: 7561348

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150